ESR1 and breast carcinoma: Interestingly, one third of endocrine resistant breast cancers are ERα-positive (Encarnación et al, 1993; Johnston et al, 1995), raising questions about the mechanisms which allow them to keep proliferating despite interfering with the estrogen response.